Analysts wait for final FDA decision on Brilinta; Atlas Genetics raises B round;

@FierceBiotech: Do pharma BOD rosters clash with biotech strategy? Story | Follow @FierceBiotech

@JohnCFierce: Novartis listed its top 7 blockbuster prospects for '11-'15. Article | Follow @JohnCFierce

> Analysts and investors are waiting for the FDA to issue its decision on Brilinta, AstraZeneca's big blockbuster hopeful. The analysts at Jefferies, at least, appear skeptical this morning. "We continue to believe that the potential for non-approval of Brilinta is high and that even if approved the product will have a lackluster launch." Release

> Dynavax Technologies Corporation today said that top-line data from its Phase III trial comparing HEPLISAV, an investigational hepatitis B virus vaccine, to a currently marketed HBV vaccine, Engerix-B, demonstrated non-inferiority, superiority and the safety of HEPLISAV. Shares of the biotech, though, dropped 17 percent this morning. Dynavax release

> The U.K.'s Atlas Genetics has completed a 16.9 million round. Release

> Following the EU's approval of Victrelis for hepatitis C Merck and Roche announced plans to expand their non-exclusive marketing pact. Story

Pharma News

@FiercePharma: Novartis Q2 shines on new meds, cost cuts. Report | Follow @FiercePharma

> Novartis' interest in buying Gen-Probe fizzles, WSJ reports. News

> Emerging markets boost Abbott's Q2 profits. Item

> Teva plans to close Montreal plant. More

Drug Delivery News

> Magnetic nanosponges could ring in a new drug-delivery method. News

> New research might take the shine off gold nanoparticles. Report

> Alnylam, MIT team up for "binary" approach to delivering siRNA. Article

> Pills may replace inhalers in half of asthma cases. Story

Medical Device News

> FDA looks to regulate medical apps. Story

> Reports: Novartis no longer persuing gen-probe. Report

> Nevro completes $58M financing round. Article

> Roche to buy German's mtm for up to $184M. Item

And Finally... A new study reports that although liars can reduce facial actions when under scrutiny, they can't suppress them all. Release

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.